TAK - Takeda Pharmaceutical • Financials

Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
03/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2023	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
03/2024	28,162	6,222	-	3%	0.3	48,039	2%	28,869	4.6	4,263	-3,175	-2,341	1,088	-15	-1,897	200%	4.4%
03/2025	30,560	7,364	-	2%	0.22	46,259	2%	27,413	3.7	6,566	-2,532	-5,012	4,033	-346	-2,018	280%	4.3%
03/2026	28,411	7,125	-	4%	0.38	46,847	3%	23,537	3.3	6,108	-2,615	-3,133	3,493	-325	-1,967	160%	3.4%

To see all financials—including updated, you must be Premium.